Gallium-68 generator
A germanium-68/gallium-68 generator is a device used to extract the positron-emitting isotope 68Ga of gallium from a source of decaying germanium-68. The parent isotope 68Ge has a half-life of 271 days and can be easily utilized for in-hospital production of generator produced 68Ga. Its decay product gallium-68 (with a half-life of only 68 minutes, inconvenient for transport) is extracted and used for certain positron emission tomography nuclear medicine diagnostic procedures, where the radioisotope's relatively short half-life and emission of positrons for creation of 3-dimensional PET scans, are useful.
Parent isotope (68Ge) source
The parent isotope germanium-68 is the longest-lived (271 days) of the radioisotopes of germanium. It has been produced by several methods.[1] In the U.S., it is primarily produced in proton accelerators: At Los Alamos National Laboratory, it may be separated out as a product of proton capture, after proton irradiation of Nb-encapsulated gallium metal.[2] At Brookhaven National Laboratories, 40 MeV proton irradiation of a gallium metal target produces germanium-68 by proton capture and double neutron knockout, from gallium-69 (the most common of two stable isotopes of gallium). This reaction is: 69Ga(p,2n)68Ge.
A Russian source produces germanium-68 from accelerator-produced helium ion (alpha) irradiation of zinc-66, again after knockout of two neutrons, in the nuclear reaction 66Zn(α,2n)68Ge.
Mechanism of generator function
When loaded with the parent isotope germanium-68, these generators function similarly to technetium-99m generators, in both cases using a process similar to ion chromatography. The stationary phase is either metal-free or alumina, TiO2 or SnO2, onto which germanium-68 is adsorbed. The use of metal-free columns allows direct labeling of 68Ga without prepurification, hence making production of gallium-68-radiolabeled compounds more convenient. The mobile phase is a solvent able to elute (wash out) gallium-68 (III) (68Ga3+) after it has been produced by electron capture decay from the immobilized (absorbed) germanium-68.
Currently, such 68Ga (III) is easily eluted with a few mL of 0.05 M, 0.1 M or 1.0 M hydrochloric acid from generators using metal-free tin dioxide[3] or titanium dioxide adsorbents, respectively, within 1 to 2 minutes. With generators of tin dioxide and titanium dioxide-based adsorbents, there once remained more than an hour of pharmaceutical preparation to attach the gallium-68 (III) as a tracer to the pharmaceutical molecules DOTATOC or DOTA-TATE, so that the total preparation time for the resulting radiopharmaceutical is typically longer than the 68Ga isotope half-life. This fact required that these radiopharmaceuticals be made on-site in most cases, and the on-site generator is required to minimize the time losses. However, new kits such as "NETSPOT" for more rapidly preparing Ga-68 edotreotide or DOTATATE from Ga-68 (III) ions have increased the flexibility of sourcing of this radiopharmaceutical for Ga-68 endocrine receptor (octreotide) scans. With NETSPOT the preparation of the Ga-68 DOTATATE is immediate once the Ga-68 has been acquired from the generator and mixed with the reagent. [4]
Indications for gallium-68 PET scanning
Gallium-67 citrate salt imaging is useful for imaging old or sterile abscesses. Gallium-68 is useful in direct tumor imaging, especially leukocyte-derived malignancies and prostate cancer metastases.
References
- Note on Ge-68 production methods in 1996. Accessed March 15, 2010
- Bach, H. T.; Claytor, T. N.; Hunter, J. F.; Olivas, E. R.; Kelsey, C. T.; Connors, M. A.; Nortier, F. M.; Runde, W. H.; Modrell, C.; Lenz, J. W.; John, K. D. (15 March 2013). "Improving the survivability of Nb-encapsulated Ga targets for the production of Ge-68". Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 299: 32–41. doi:10.1016/j.nimb.2013.01.035.
- Loc'h C, Mazièré B, Comar D (1980). "A new generator for ionic gallium-68". Journal of Nuclear Medicine. 21 (2): 171–3. PMID 6965408.
- "The Clinical Impact of Utilizing NETSPOT - DMS Health". 19 September 2019.